Patents by Inventor Guus Hateboer
Guus Hateboer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7604960Abstract: Described is a method for producing a protein of interest, the method comprising: a) providing a recombinant adenoviral vector comprising nucleic acid encoding the protein of interest under control of a promoter, wherein the adenoviral vector has deletions in a first region and in a second region of the adenovirus genome, wherein each of the first region and the second region is required for adenoviral genome replication and/or adenovirus particle formation, b) propagating the adenoviral vector in a first type of complementing cells that express proteins from the first and from the second region of the adenovirus genome so as to complement the deletions of the recombinant adenoviral vector, to obtain recombinant adenovirus particles, c) infecting a culture of a second type of complementing cells with the recombinant adenovirus particles, wherein the second type of complementing cells express protein from the first region of the adenovirus genome but not protein from the second region of the adenovirus genome,Type: GrantFiled: June 1, 2007Date of Patent: October 20, 2009Assignee: Crucell Holland B.V.Inventors: Guus Hateboer, Menzo J. E. Havenga, Ronald Vogels, Lennart Holterman
-
Patent number: 7491532Abstract: Methods and compositions for the production of recombinant proteins in a eukaryotic cell line are disclosed. The methods and compositions are particularly useful for generating stable expression of recombinant proteins of interest that are modified post-translationally, for example, by glycosylation. Such proteins may have advantageous properties in comparison with their counterparts produced in non-human systems such as Chinese hamster ovary cells.Type: GrantFiled: March 1, 2004Date of Patent: February 17, 2009Assignee: Crucell Holland, B.V.Inventors: Abraham Bout, Guus Hateboer, Karina Cornelia Verhulst, Alphonsus Gerardus Uytdehaag, Govert Johan Schouten
-
Patent number: 7470523Abstract: Methods and compositions for the production of recombinant proteins in a human cell line. The methods and compositions are particularly useful for generating stable expression of human recombinant proteins of interest that are modified post-translationally, for example, by glycosylation. Such proteins may have advantageous properties in comparison with their counterparts produced in non-human systems such as Chinese hamster ovary cells.Type: GrantFiled: November 3, 2006Date of Patent: December 30, 2008Assignee: Crucell Holland B.V.Inventors: Abraham Bout, Guus Hateboer, Karina Cornelia Verhulst, Alphonsus Gerardus Uytdehaag, Govert John Schouten
-
Publication number: 20080274497Abstract: Methods and compositions for the production of recombinant proteins in a eukaryotic cell line are disclosed. The methods and compositions are particularly useful for generating stable expression of recombinant proteins of interest that are modified post-translationally, for example, by glycosylation. Such proteins may have advantageous properties in comparison with their counterparts produced in non-human systems such as Chinese hamster ovary cells.Type: ApplicationFiled: March 1, 2004Publication date: November 6, 2008Inventors: Abraham Bout, Guus Hateboer, Karina Cornelia Verhulst, Alphonsus Gerardus Uytdehaag, Govert Johan Schouten
-
Publication number: 20080113409Abstract: Described is a method for producing a protein of interest, the method comprising: a) providing a recombinant adenoviral vector comprising nucleic acid encoding the protein of interest under control of a promoter, wherein the adenoviral vector has deletions in a first region and in a second region of the adenovirus genome, wherein each of the first region and the second region is required for adenoviral genome replication and/or adenovirus particle formation, b) propagating the adenoviral vector in a first type of complementing cells that express proteins from the first and from the second region of the adenovirus genome so as to complement the deletions of the recombinant adenoviral vector, to obtain recombinant adenovirus particles, c) infecting a culture of a second type of complementing cells with the recombinant adenovirus particles, wherein the second type of complementing cells express protein from the first region of the adenovirus genome but not protein from the second region of the adenovirus genome,Type: ApplicationFiled: June 1, 2007Publication date: May 15, 2008Inventors: Guus Hateboer, Menzo J. E. Havenga, Ronald Vogels, Lennart Holterman
-
Publication number: 20070054394Abstract: Methods and compositions for the production of recombinant proteins in a human cell line. The methods and compositions are particularly useful for generating stable expression of human recombinant proteins of interest that are modified post-translationally, for example, by glycosylation. Such proteins may have advantageous properties in comparison with their counterparts produced in non-human systems such as Chinese hamster ovary cells.Type: ApplicationFiled: November 3, 2006Publication date: March 8, 2007Inventors: Abraham Bout, Guus Hateboer, Karina Verhulst, Alphonsus Uytdehaag, Govert Schouten
-
Patent number: 7132280Abstract: Methods and compositions for the production of recombinant proteins in a human cell line. The methods and compositions are particularly useful for generating stable expression of human recombinant proteins of interest that are modified post-translationally, for example, by glycosylation. Such proteins may have advantageous properties in comparison with their counterparts produced in non-human systems such as Chinese hamster ovary cells.Type: GrantFiled: September 3, 2002Date of Patent: November 7, 2006Assignee: Crucell Holland, B.V.Inventors: Abraham Bout, Guus Hateboer, Karina Cornelia Verhulst, Alphonsus Gerardus Uytdehaag, Govert Johan Schouten
-
Patent number: 6855544Abstract: Methods and compositions for the production of recombinant proteins in a human cell line. The methods and positions are particularly useful for generating stable expression of human recombinant proteins of interest that are modified post-translationally, for example, by glycosylation. Such proteins may have advantageous properties in comparison with their counterparts produced in non-human systems such as Chinese Hamster Ovary cells.Type: GrantFiled: April 14, 2000Date of Patent: February 15, 2005Assignee: Crucell Holland B.V.Inventors: Guus Hateboer, Karina Cornelia Verhulst, Govert Johan Schouten, Alphonsus Gerardus Uytdehaag, Abraham Bout
-
Publication number: 20030157494Abstract: The present invention discloses novel smooth muscle cell specific promoters and uses thereof. The promoters are suited for providing nucleic acid of interest with the capability of expressing specifically in a contractile smooth muscle cell, preferably a vascular contractile smooth muscle cell and/or a visceral contractile smooth muscle cell. One example of such a promoter is a smoothelin gene promoter. For gene therapy purposes said smoothelin gene promoter is preferably derived from a human. A promoter of the invention may be incorporated into nucleic acid delivery vehicle. The nucleic acid delivery vehicle preferably comprises a virus-like particle such as an adenovirus particle, an adeno-associated virus particle or a retrovirus particle.Type: ApplicationFiled: March 8, 2002Publication date: August 21, 2003Applicant: Universiteit MaastrichtInventors: Guillaume Johannes J. M. van Eijs, Guus Hateboer, Menzo Jans E. Havenga
-
Publication number: 20030092160Abstract: Methods and compositions for the production of recombinant proteins in a human cell line. The methods and compositions are particularly useful for generating stable expression of human recombinant proteins of interest that are modified post-translationally, for example, by glycosylation. Such proteins may have advantageous properties in comparison with their counterparts produced in non-human systems such as Chinese hamster ovary cells.Type: ApplicationFiled: September 3, 2002Publication date: May 15, 2003Inventors: Abraham Bout, Guus Hateboer, Karina Cornelia Verhulst, Alphonsus Gerardus Uytdehaag, Govert Johan Schouten
-
Patent number: 5985283Abstract: The present invention relates to a transcription inhibiting factor, designated BS69. The factor can bind to both the 243R and 289R E1A adenovirus proteins, inhibiting the transactivating activity of the latter.Type: GrantFiled: December 12, 1997Date of Patent: November 16, 1999Assignee: Prolifix LimitedInventors: Guus Hateboer, Rene Bernards